A commercial offer, a clinical eligibility rule, and a research finding require different evidence. This comparison uses CoreAge Rx and Pallas Health to show why those categories should remain separate when reviewing sermorelin providers.
CoreAge Rx holds featured placement through a commercial relationship. That ordering does not establish a medical advantage. We checked public sources on September 23, 2026, without enrolling or assessing patient outcomes.
A commercial offer, a clinical eligibility rule, and a research finding require different evidence. This comparison uses CoreAge Rx and Pallas Health to.
Start with the actual price claims
CoreAge Rx advertises a starting price of $99 monthly. Pallas advertises a $139 introductory month followed by $597 every 12 weeks under its displayed offer. Neither figure is a verified quote for every patient.
Keep starting and introductory qualifications visible, then confirm the selected plan. A 12-week interval is 84 days and should not be silently described as three calendar months. Price clarity is useful, but it is not a measurement of clinical effectiveness.
Compare eligibility with research applicability
Pallas's FAQ limits its program to adults age 55 and under. Its references include historical studies of older adults and a related GHRH analog. The population-and-age guide explains why that distinction needs a clinician's interpretation.
Ask either provider which evidence relates to the actual preparation, patient circumstances, and intended outcome. Do not assume that appearing within an enrollment range establishes likely benefit or that a reference list is a trial of the provider itself.
| Claim under review | What to check |
|---|---|
| Advertised price | Current offer and conditions |
| Program eligibility | Applicable provider policy and individual assessment |
| Study finding | Actual participants, intervention, duration, and measured outcome |
| Product benefit | Relevance of the evidence to the specific preparation and patient |
Keep study limitations visible
Our small-study guide examines two historical abstracts and their limits. A favorable endpoint does not erase unchanged outcomes, and short follow-up cannot settle every long-term question.
The FDA's compounding guidance addresses the separate fact that compounded drugs are not FDA-approved. Research references do not change that status.
The full CoreAge review and Pallas review provide provider context. We have not verified a clinical winner. The comparison is strongest when each conclusion stays within what its source can actually establish.
The source notes
Sources & further reading
Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Check the dated discussion in each article for the scope of our research; offers can change.